{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-058960","form_type":"8-K","ticker":"FENC","cik":"0001211583","company_name":"FENNEC PHARMACEUTICALS INC.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.582537+00:00","generated_at":"2026-06-02T04:58:48.774574+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"medium","headline":"Fennec Pharma to report Q1 2024 results on May 14; conference call at 8:30am ET","bullets":["First quarter 2024 financial results to be released before U.S. market open on Tuesday, May 14, 2024.","Management to host conference call at 8:30 a.m. ET on May 14; registration required for dial-in.","Webcast and replay archived on www.fennecpharma.com for 30 days.","PEDMARK received FDA approval in September 2022; PEDMARQSI approved in EU (June 2023) and UK (Oct 2023).","Company is commercial-stage specialty pharma focused on pediatric platinum-induced ototoxicity."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-058960","json":"https://secwatch.observer/filing/0001104659-24-058960.json","markdown":"https://secwatch.observer/filing/0001104659-24-058960.md","text":"https://secwatch.observer/filing/0001104659-24-058960.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1211583/000110465924058960/0001104659-24-058960-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1211583/000110465924058960/tm2413869d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T04:58:48.774574+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}